Eurolab, an exclusive marketing partner of Adalvo in South Africa, has successfully defended its right to provide affordable cancer treatment by revoking the Enzalutamide compound patent, originally set to expire in March 2026, despite a legal challenge from a multinational pharmaceutical corporation.
This landmark judgment by the Court of the Commissioner of Patents sets a critical precedent for the pharmaceutical industry and intellectual property law, particularly in patent enforcement. As the first to launch a high-quality, cost-effective alternative in the market, Eurolab reaffirms its commitment to ensuring accessible healthcare for South African cancer patients.
Prostate cancer is the leading cause of cancer-related deaths in men, highlighting the urgent need for accessible treatment options. With this launch, Adalvo and Eurolab, ensure that patients in South Africa gain earlier access to a cost-effective alternative to the originator product.
“Bringing Enzalutamide to South Africa ahead of the original patent expiry demonstrates our ability in navigating complex regulatory and market access landscapes, delivering high-value treatments where they are needed the most,” says Anil Okay, CEO of Adalvo. “This launch reflects our commitment to improving patient access to critical oncology therapies worldwide.”
Lynne du Toit, CEO of Eurolab, adds, “Eurolab is committed to making as many quality, affordable cancer treatments available to all South Africans. Because of the favourable ruling, Eurolab can continue to market and sell Enzutix in the South African market through wholesalers and all pharmacy chains. It’s a win not only for Eurolab, but also for all the South African patients who are desperately in need of the product at an affordable price.”
For collaboration opportunities, contact Adalvo’s Business Development team.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 19 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Eurolab
Eurolab is the largest and leading oncology company in South Africa with a focus on generics and biosimilars. Our experienced and award-wining leadership team brings a unique and dynamic edge to Eurolab, allowing us to have established ourselves as a trusted partner in the South African pharmaceutical landscape. We have a full in-house industry leading regulatory and pharmacovigilance team who bring an additional layer of expertise, knowledge, and help expedite the regulatory approval process by efficiently navigating the regulatory pathways and requirements.
Since 2011, Eurolab marked a significant step towards diminishing the financial burdens associated with cancer care in South Africa. Our unwavering commitment to ensuring access to high quality medicines is what distinguishes us, ultimately making cancer treatment a more attainable reality for a wider segment of the population.
With Eurolab’s comprehensive approach, we have expanded and integrated innovative technology and medicines into South Africa’s cancer care environment. We have created access to diverse options for cancer treatment and recovery with our broad portfolio of oncology and haematology products.
Disclaimer: The decision may be subject to appeal. Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.